4.5 Article

Iron deficiency and iron deficiency anaemia in women

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.bpobgyn.2016.09.007

关键词

iron deficiency; iron deficiency anaemia; anaemia; heavy menstrual bleeding; hepcidin

资金

  1. Bayer
  2. Aspen
  3. Astellas
  4. Consilient Healthcare
  5. HRA Pharma
  6. Mithra
  7. Merck
  8. Pfizer
  9. Vifor Pharma
  10. Bayer Healthcare
  11. Merck/MSD

向作者/读者索取更多资源

Iron deficiency (ID) is the most common micronutrient deficiency worldwide with >20% of women experiencing it during their reproductive lives. Hepcidin, a peptide hormone mostly produced by the liver, controls the absorption and regulation of iron. Understanding iron metabolism is pivotal in the successful management of ID and iron deficiency anaemia (IDA) using oral preparations, parenteral iron or blood transfusion. Oral preparations vary in their iron content and can result in gastrointestinal side effects. Parenteral iron is indicated when there are compliance/tolerance issues with oral iron, comorbidities which may affect absorption or ongoing iron losses that exceed absorptive capacity. It may also be the preferred option when rapid iron repletion is required to prevent physiological decompensation or given preoperatively for non-deferrable surgery. As gynaecologists, we focus on managing women's heavy menstrual bleeding (HMB) and assume that primary care clinicians are treating the associated ID/IDA. We now need to take the lead in diagnosing, managing and initiating treatment for ID/IDA and treating HMB simultaneously. This dual management will significantly improve their quality of life.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据